Rumana Haque-Ahmed
Chief Regulatory Officer
Rumana Haque-Ahmed joined Taysha Gene Therapies in 2021 and has served as Chief Regulatory Officer since 2024.
Rumana is an accomplished regulatory affairs leader with over 30 years of experience driving global regulatory strategy and product development across multiple therapeutic areas, with a proven record of shaping innovative approval strategies for rare disease and antiviral therapeutics. Before joining Taysha, Rumana spent 13 years at Sanofi in roles of increasing responsibility, culminating in her role as Head of International Regulatory Affairs, based in Singapore. In this role, she established and managed a regulatory function of over 300 people across Africa, Eurasia, Latin America and the Middle East. Prior to Sanofi, Rumana served as Regulatory Therapeutic Area Head for Genzyme/Sanofi’s rare disease portfolio, where she developed and executed global regulatory plans that resulted in multiple product approvals for rare diseases. Rumana has also held various roles in regulatory affairs at Idenix Pharmaceuticals (acquired by Merck & Co.), Curis, Genzyme (acquired by Sanofi) and Sanofi.
Rumana earned a B.Pharm from Memorial University, Newfoundland and Labrador.
